Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Photo of hand with glucose monitor showing 5.5 reading above it.

The TriMaster patient preference study results were presented on Wednesday December 7 2022 at the 2022 IDF World Diabetes Congress in Lisbon, Portugal, with two papers published simultaneously in eNature Medicine.

TriMaster was a randomised double-blind, three-way crossover trial run by the MASTERMIND consortium, a collaboration between the Royal Devon University Healthcare NHS Foundation Trust and the universities of Oxford, Glasgow and Dundee. It was performed by Exeter NIHR Clinical Trials Unit and 24 hospitals throughout the UK, including the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM) Clinical Research Unit.

People with type 2 diabetes received three different second or third line once-daily glucose-lowering drugs (pioglitazone, sitagliptin and canagliflozin), and it was the first trial to allow people to choose their own medication after trying three different drugs in succession. It showed that allocating therapy based on individually preferred drugs, rather than giving everyone the overall most preferred drug, would result in more people achieving the lowest HbA1c for them (70% vs. 30%) as well as the fewest side effects (67% vs. 50%).

Professor Rury Holman from the Diabetes Trial Unit, who led on the Oxford contribution to the trial,  said "This precision medicine trial supports the use of simple routinely available clinical measures to identify the type of drug most likely to deliver the most effective glucose lowering for a given person with type 2 diabetes."

We want to hear about your news!

Publishing a paper? Just won an award? Get in touch with communications@rdm.ox.ac.uk

 

Similar stories

2022 RDM Graduate Prize Winners

This year's winners are Edward Jenkins, Antje Rottner, and Akshay Shah.

Enterprise Associate Interview with Dr Shilpa Nagarajan

Dr Shilpa Nagarajan is one of the MPLS Enterprise and Innovation Fellows for 2022-23.

Intensive blood glucose control for people with type 2 diabetes when they are first diagnosed reduces diabetic complications and prolongs life

The study, which tracked volunteers for up to 44 years, showed that the benefits of early intensive blood glucose control can persist for decades.

Major research network to investigate body clock and stroke

The University of Oxford is part of a new international research network to investigate the interactions between the biology of the body's internal clock and the disordered physiological processes associated with stroke.